GlassScriptPhysician profile
Lauren A Mcdonald
NPI 1366413288
$49,778.04
in general payments reported to CMS, 2019-2025
23 companies · $48K in 2025
The $48K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $35.22 · 2022: $140 · 2023: $612 · 2024: $646 · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Consulting Fee: $6,302 · Food and Beverage: $2,586 · Travel and Lodging: $2,236 · Education: $68.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,000.00 |
| Consulting Fee | $6,301.97 |
| Food and Beverage | $2,585.58 |
| Travel and Lodging | $2,236.32 |
| Education | $68.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41,480.66 | 2019-2025 | Krystexxa, Tavneos |
| Calliditas Therapeutics US INC. | $4,625.11 | 2025 | Tarpeyo |
| Genentech USA, INC. | $1,832.00 | 2025 | Gazyva |
| Horizon Therapeutics Plc | $493.36 | 2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $148.48 | 2019-2025 | Jynarque |
| Shield Therapeutics INC | $146.43 | 2024 | |
| Aurinia Pharma U.S., INC. | $115.56 | 2022-2024 | Lupkynis |
| Vifor Pharma, INC. | $112.95 | 2019-2024 | Veltassa |
| Genentech, INC. | $109.91 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $93.87 | 2019-2024 | Farxiga |
| Travere Therapeutics, INC. | $88.09 | 2023-2025 | |
| Glaxosmithkline, LLC. | $82.46 | 2022-2024 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $75.86 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $69.13 | 2019-2025 | Ultomiris |
| Akebia Therapeutics INC | $67.11 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $55.97 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $45.57 | 2023-2024 | Ozempic, Rybelsus |
| Fresenius USA Marketing, INC. | $38.79 | 2019-2024 | Velphoro |
| Recor Medical INC | $25.26 | 2024 | Paradise Renal Denervation System |
| Amicus Therapeutics, INC. | $20.78 | 2020 | |
| Mallinckrodt Enterprises LLC | $19.65 | 2019 | |
| Scpharmaceuticals INC. | $16.09 | 2025 | |
| Novartis Pharmaceuticals Corporation | $14.95 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.